Aptorum Group Limited: Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce that the United States

Related Keywords

United States ,Singapore ,American ,Darren Lui ,Ghislaine Gasparetto ,Aptorum Group Form ,Aptorum Group Or ,Technologies Pte Ltd ,Investor Relations Department ,Drug Administration ,Singapore Agency For Science ,Actifin Financial Communications Europe ,Redchip Financial Communications United States ,Daptorum Group ,Aptorum Group Limited Nasdaq ,American Cancer Society ,Regulatory News ,Group Limited ,Euronext Paris ,United States Food ,Orphan Drug Designation ,Investigational New Drug Application ,Executive Director ,American Cancer ,Accelerate Technologies Pte Ltd ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Relations Department ,Financial Communications United States ,Financial Communications Europe ,Aptorum ,Group ,Imited ,Eceives ,Orphan ,Drug ,Resignation ,Fact ,Repurposed ,Treatment ,Neuroblastoma ,